CompanyAGMBNasdaqAntwerpen

AgomAb Therapeutics NV

AgomAb Therapeutics develops disease-modifying therapies for fibro-inflammatory diseases.

SEC EDGAR ClinicalTrials.gov ir.agomab.com

6-KOct 1Latest SEC filing

Oct 1Latest story

October 2026

Agomab reports positive OLE data for ontunisertib in Crohn's bowel strictures

Oct 1Clinical readoutAgomAb Therapeutics NV ontunisertib

September 2026

Agomab reports positive Phase 1 data for inhaled IPF drug AGMB-447, plans Phase 2

Sep 14Clinical readoutAgomAb Therapeutics NV

August 2026

Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats

Aug 10PeopleAgomAb Therapeutics NV

Agomab reports first-half 2026 results, confirms FDA alignment on Crohn's trial design

Aug 6Clinical readoutAgomAb Therapeutics NV

July 2026

Agomab registers Phase 2b trial of ontunisertib in fibrostenosing Crohn's disease

Jul 6Trial updateAgomAb Therapeutics NV ontunisertib

June 2026

Agomab Spain registers Phase 1 mass balance trial of ontunisertib in healthy volunteers

Jun 29Trial updateAgomAb Therapeutics NV ontunisertib